ArticleAIDS (London, England)2015
Lung cancer incidence and survival among HIV-infected and uninfected women and men.
Article in AIDS (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Human immunodeficiency virus infection and mortality risk among lung cancer patients: A systematic review and meta-analysis.Medicine · 2018Pooled it
- Longitudinal Risk Factors for Incident Lung Cancer Among a Mixed HIV Serostatus Cohort of Sexual Minority Men in the United States.AIDS education and prevention : official publication of the International Society for AIDS Education · 2026Article
- Sex- and age- specific lung cancer incidence and mortality among Medicaid beneficiaries with and without HIV, 2001-2015.BMC cancer · 2026Article
- The tumor microenvironment of non-small cell lung cancer impairs immune cell function in people with HIV.The Journal of clinical investigation · 2025Article
- Pulmonary Immunocompromise in Human Immunodeficiency Virus Disease.Clinics in chest medicine · 2025Review
- Human immunodeficiency virus-related renal cell carcinoma: a 13.5-year experience.AIDS research and therapy · 2025Article
- State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI.International journal of cancer · 2024Review
- Review
- A health equity framework to support the next generation of cancer population simulation models.Journal of the National Cancer Institute. Monographs · 2023Article
- The global burden of lung cancer: current status and future trends.Nature reviews. Clinical oncology · 2023Review
- HIV-associated lung disease.Nature reviews. Disease primers · 2023Review
- Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study.The lancet. HIV · 2022Article
- Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients.Scientific reports · 2022Article
- HIV-Associated Cancer Biomarkers: A Requirement for Early Diagnosis.International journal of molecular sciences · 2021Review
- Clinical features of HIV-infected patients with non-small-cell lung cancer after lung resection.General thoracic and cardiovascular surgery · 2020Article
- Global Epidemiology of Lung Cancer.Annals of global health · 2019Review
- HIV-1 Nef promotes cell proliferation and microRNA dysregulation in lung cells.Cell cycle (Georgetown, Tex.) · 2019Article
- Are Non-HIV Malignancies Increased in the HIV-Infected Population?Current infectious disease reports · 2018Review
- [Individualized Comprehensive Therapy for the Lung Cancer Patients with HIV Infection].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Article
- Recent advances in cancer outcomes in HIV-positive smokers.F1000Research · 2018Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
objectivesTo determine the lung cancer incidence and survival time among HIV-infected and uninfected women and men.
designTwo longitudinal studies of HIV infection in the United States.
methodsData from 2549 women in the Women's Interagency HIV Study (WIHS) and 4274 men in the Multicenter AIDS Cohort Study (MACS), all with a history of cigarette smoking, were analyzed. Lung cancer incidence rates and incidence rate ratios were calculated using Poisson regression analyses. Survival time was assessed using Kaplan-Meier and Cox proportional-hazard analyses.
resultsThirty-seven women and 23 men developed lung cancer (46 HIV-infected and 14 HIV-uninfected) during study follow-up. In multivariable analyses, the factors that were found to be independently associated with a higher lung cancer incidence rate ratios were older age, less education, 10 or more pack-years of smoking, and a prior diagnosis of AIDS pneumonia (vs. HIV-uninfected women). In an adjusted Cox model that allowed different hazard functions for each cohort, a history of injection drug use was associated with shorter survival, and a lung cancer diagnosis after 2001 was associated with longer survival. In an adjusted Cox model restricted to HIV-infected participants, nadir CD4 lymphocyte cell count less than 200 was associated with shorter survival time.
conclusionsOur data suggest that pulmonary damage and inflammation associated with HIV infection may be causative for the increased risk of lung cancer. Encouraging and assisting younger HIV-infected smokers to quit and to sustain cessation of smoking is imperative to reduce the lung cancer burden in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.